ATS Medical: First human being robot assisted endoscopic aortic valve alternative in the Midwest ATS Medical, Inc UK drugstore . Balkhy, M.D., at the Wisconsin Heart Medical center in Milwaukee, Wisconsin. The ATS 3f Aortic Bioprosthesis is certainly uniquely suited for use in minimally invasive techniques, in robot-assisted aortic valve replacement especially. Balkhy. With the introduction of the ATS 3f Aortic Bioprosthesis to the U.S. Marketplace, surgeons have quickly known its unique prospect of use in much less invasive port access and robot assisted methods. Balkhy is just the next one of these methods in the usa to become performed with robotic assist, and is another essential step toward providing surgeons and individuals better options for the treating structural heart disease without an open up sternotomy.
, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 research evaluating tivozanib for the treatment of advanced renal cell carcinoma will be offered at the Ninth International Kidney Tumor Symposium in Chicago, Illinois, October 1-2, 2010.D., Sc.M., chief medical officer at AVEO. We think that there is an urgent dependence on a differentiated kidney cancers therapy with strong efficacy and favorable tolerability, and we anticipate continuing collaboration with the Kidney Cancer tumor Association, clinicians and patients as we make initiatives to progress tivozanib toward regulatory approval. The Phase 2 scientific trial evaluated tivozanib in 272 sufferers with advanced RCC.